Skip to content

Early Palliative Care in Patient With Acute Leukaemia

Impact on Quality of Life of an Early Management Supportive Care of Patients With Acute Leukemia in First Relapse.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02631811
Acronym
Pablo Hemato
Enrollment
49
Registered
2015-12-16
Start date
2016-02-09
Completion date
2020-10-01
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukaemia in Relapse

Keywords

acute leukaemia, supportive / palliative care

Brief summary

Several studies have shown that patients with acute leukemia have many symptoms during disease These symptoms decrease the quality of life and may even appear or worsen other symptoms such as depression Several studies point to the involvement of supportive care and palliative care is delayed in these patients The aim of this study is to evaluate the impact on the quality of life of an early and standardized involvement of a support / palliative care team for patients with acute leukemia in first relapse compared to a control group .

Interventions

OTHERSupportive /palliative care intervention

patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \> 18 years old * acute lymphoblastic or myeloblastic leukemia at first relapse and diagnosed within 8 weeks before inclusion. * Patients in whom a curative strategy (transplant) is not considered. * patients older that 75 years at the diagnosis * informed signed consent

Exclusion criteria

* unable to answer the questionnaire * psychiatric disorders other than depression * persons under guardianship

Design outcomes

Primary

MeasureTime frameDescription
mesure of quality of life12 weeksQuality of life measured by FACT Leu questionnaire. score of quality of life will be compared between the 2 groups

Secondary

MeasureTime frameDescription
measure of symptoms intensity12 weeksSymptom intensity measured by ESAS questionnaire. Score of symptoms intensity will be compared between the 2 groups
measure of depression12 weeksscore of depression measured by HADS questionnaire. Score of depression will be compared between the 2 groups
measure of anxiety12 weeksscore of anxiety measured by HADS questionnaire. score of anxiety will be compared between the 2 groups
measure of the quality of the end of lifeup to 9 monthsWithin the last month of life, several parameters will be studied to evaluate the quality of the end of life like number of admission in emergency unit.
overall survival9 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026